TESARO (TSRO) Posts Q4 Loss of $2.60/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TESARO Announces Fourth-Quarter 2016 Operating Results
February 28, 2017 4:05 PM ESTNiraparib NDA under review by FDA; pre-launch preparations for planned commercial launch well underwayExpanded access program (EAP) for niraparib open in U.S.; European EAP expected to open 1H 2017Positive opinion rendered for VARUBY® by the European Medicine Agencys CHMP; European launch planned for 2Q 2017International headquarters and European operations established to cover 17 target countriesRegistration program for niraparib in lung cancer to be finalized in 1H 2017TSR-042 (anti-PD-1 antibody) registration program to initiate in 2Q 2017Cash and cash equivalents totaled... More
